Cruise Ship Hantavirus Outbreak: Andes Virus Cases Highlight Need for Rapid Testing

In May 2026, the MV Hondius expedition cruise ship made international headlines after at least eight passengers fell ill with confirmed Andes virus infections, resulting in three deaths—a case fatality rate of roughly 38%. Passengers hailed from multiple countries, and the outbreak prompted alerts from WHO and ECDC.

Andes virus, a New World hantavirus primarily found in South America, is notable for its rare potential for limited person-to-person transmission. While the overall public risk remains low, this outbreak highlights the importance of fast and accessible diagnostics for travelers, clinics, and public health teams.

What Is Hantavirus and the Andes Virus?

Hantaviruses are rodent-borne viruses causing two main syndromes:

• Hemorrhagic Fever with Renal Syndrome (HFRS) – Common in Asia and Europe (“Old World” hantaviruses).
• Hantavirus Pulmonary Syndrome (HPS) – Found in the Americas (“New World”), causing severe respiratory distress.

The Andes virus (ANDV) triggers HPS and spreads primarily through contact with infected rodent urine, droppings, or saliva, often via aerosolized particles. Incubation typically ranges from 4 to 42 days. Unique among hantaviruses, Andes virus can occasionally transmit between people in close-contact settings.

The MV Hondius outbreak likely began with rodent exposure in South America, followed by limited secondary spread aboard the confined cruise ship environment.

HPS Symptoms: Early Recognition Is Critical

Early symptoms often mimic common illnesses:

• High fever
• Fatigue
• Muscle aches (back, hips, thighs)
• Headache and dizziness
• Gastrointestinal issues (nausea, vomiting, diarrhea)

As HPS progresses, patients may develop:

• Rapid-onset cough
• Shortness of breath
• Pulmonary edema leading to respiratory failure and cardiogenic shock

Early supportive care significantly improves survival rates. Therefore, differentiating hantavirus from flu, COVID-19, or other respiratory infections is essential, especially for returning travelers.

Limitations of Traditional Hantavirus Diagnosis

PCR and ELISA tests offer high accuracy but often require specialized laboratories, trained personnel, and several hours to days for results. In travel clinics, remote settings, or during early outbreak response, these delays can slow down clinical decisions and contact tracing.

This is where point-of-care Hantavirus rapid tests provide clear advantages.

Hantavirus IgM/IgG Rapid Test: Point-of-Care Detection

Point-of-care Hantavirus IgM/IgG rapid tests provide fast and reliable detection of Andes virus and other hantavirus strains, suitable for travel medicine, clinics, and outbreak response.

Key Features:

• Results in 10–15 minutes
• Compatible with whole blood, serum, or plasma
• Lateral flow immunoassay — simple cassette, no instruments required
• Combo IgM/IgG detection for acute and recent infections
• CE/IVDD-Certified for quality assurance

Main Benefits in Clinical Settings:

• Enables true point-of-care testing in travel clinics, hospitals, cruise ship medical facilities, and field environments
• Supports rapid differential Hantavirus diagnosis against flu, COVID-19, and other common respiratory illnesses
• Allows quicker screening of symptomatic returning travelers for timely patient management and outbreak screening

Comparison: Hantavirus Rapid Test vs Lab Methods

Recent outbreaks like the MV Hondius incident demonstrate how accessible rapid diagnostics can support healthcare providers in making faster, informed decisions.

Who Should Consider Hantavirus Testing?

• Passengers or crew returning from South American cruises or expeditions
• Individuals with flu-like symptoms after potential rodent exposure
• Travel medicine clinics screening high-risk patients
• Public health teams managing clusters

Prevention Remains Key

• Avoid rodent-infested areas and properly clean spaces with droppings
• Use PPE and ventilation during cleanup
• Practice hand hygiene and avoid close contact with symptomatic individuals (for Andes virus)
• Travelers should monitor symptoms for up to 6 weeks post-exposure

There is currently no specific antiviral treatment or vaccine. Care focuses on supportive management in hospital settings.

Conclusion: Preparedness Through Rapid Diagnostics

The 2026 MV Hondius Andes virus outbreak serves as a reminder that zoonotic threats can emerge in unexpected settings. While widespread transmission risk is low, having accessible diagnostic tools strengthens preparedness.

For laboratories, travel clinics, and healthcare providers looking for reliable hantavirus detection solutions, Medotex offers a high sensitive Hantavirus IgM/IgG Rapid Test.

Contact Medotex to learn more about product specifications, bulk ordering, and implementation support.

Stay informed and prepared.

Source:

WHO: Hantavirus cluster linked to cruise ship travel, Multi-country

CDC: About Andes Virus